Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TransOral Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Many biotechs specializing in drug delivery techniques--including TransOral Pharmaceuticals Inc.--are working to speed the onset of drug action for existing therapeutics. For example, in drugs for pain, the faster a drug's onset of action, the faster the pain relief. TransOral, founded in January 2002, is trying a transmucosal approach, but is directing its efforts solely at the tissues of the mouth by developing lozenges, gum, and similar dosage forms.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts